Recent evidence from our laboratory and others have suggested that the mechanism for a decrease in resting blood pressure after an acute bout of exercise is a centrally mediated decrease in total peripheral resistance. This study examined the effect of the central serotonergic system on post exercise hypotension (PEH) in 11 borderline hypertensive individuals (nine male, two female) aged 24.5 ؎ 5.1 years. Each subject completed two, 30-min cycling bouts at 70% of V O 2 Peak while under placebo or a selective serotonin re-uptake inhibitor (SSRI) treatment. Blood pressure was recorded directly from the radial artery, and treatments were randomised, double blinded and separated by at least 14 days. Baseline blood pressure was 145/72 mm Hg for systolic (SBP) and diastolic (DBP) respectively. Peripheral measures of serotonin (5-HT) were lower under SSRI treatment, whereas the major 5-HT metabolite, 5-hydroxyindoleacetic acid, was not significantly changed,
Introduction
A growing body of literature has confirmed that an acute bout of exercise can cause a transient decrease in the normal resting blood pressure and may last up to several hours. [1] [2] [3] This phenomenon is particularly evident in hypertensive and borderline hypertensive individuals and has been termed post exercise hypotension (PEH). This decrease in blood pressure could be caused by a decreased cardiac output (Q c) or decreased total peripheral resistance (TPR) (or both). Since oxygen uptake (V O 2 ) and heart rate (HR) equal or exceed pre-exercise values during the post exercise hypotensive state 2 it is unlikely that there is a significant decrease in Q c. This suggests that PEH is a function of decreased TPR.
A decrease in TPR can be the result of centrally mediated mechanisms (eg, decreased efferent activity from the sympathetic nervous system (SNS)) or locally mediated vasodilation (eg, in response to locally released metabolites and compounds). The finding that the magnitude of the PEH is largely independent of exercise intensity, 4 exercise duration 5 or the size of the exercising muscle group 6 argues against a local mechanism. In addition, PEH persists long after body temperature, circulating exercise metabolites or ionic imbalances have returned to normal. It has been shown that exercise induced alterations in the opioid system centrally affect blood pressure. 7 Although little is known about the mechanics of the opioid system, it may moderate sympathetic activity. 7 Specifically, ␤-endorphins are known to increase during exercise, and are often claimed to be responsible for the sensation of euphoria that accompanies moderate intensity endurance exercise. 8 Early work examining ␤-endorphins and blood pressure found that infusion of ␤-endorphins resulted in a prolonged drop in blood pressure. 9 Those studies that have examined the contribution of the ␤-endorphins to PEH have found contradictory results when the opioid system was blocked with naloxone, an opioid receptor antagonist. 7, 10 A chemical link has been established between the serotonergic system and the endorphins. Preliminary animal studies have found a significant drop in blood pressure following infusion of ␤-endorphins. However, no hypotension was found if ␤-endorphins were infused into animals pre-treated with pCPA, a specific depletor of serotonin (5-HT). 9 Additionally, the hypotensive effect of the ␤-endorphins was potentiated by fluoxetine, a specific serotonin re-uptake inhibitor (SSRI). 9 Collectively, these results imply that ␤-endorphins are a stimulus for 5-HT release, and that 5-HT itself, or in conjunction with ␤-endorphins cause a decrease in sympathetic outflow.
Although the exact location of the central hypotensive effects of 5-HT remains unknown, it appears that it may be mediated by specific 5-HT1A receptors in the brain. 11 Centrally administered 8-OH-DPAT, a 5-HT1A receptor agonist, has been shown to decrease blood pressure and sympathetic nerve activity. 12 The sites of 5-HT release in the periphery are the gut and intestines. 13 Both of these areas have minimal blood flow during exercise. Furthermore, peripheral 5-HT has been shown to act on 5-HT2 receptors and cause vasoconstriction 14, 15 and is cleared rapidly via monoamine oxidase. 16 Therefore, the purpose of this investigation was to examine the effects of central 5-HT on the magnitude of the blood pressure decrements after acute exercise. Central 5-HT levels were manipulated by treatment with an SSRI. It was hypothesised that the increases in 5-HT elicited by the SSRI may potentiate PEH.
Methods

Participants
Eleven participants (nine males, two females), not actively involved in intense exercise programmes and with borderline systolic hypertension (145 Ϯ 15/72 Ϯ 10 mm Hg) (mean Ϯ s.d.) volunteered to participate in this study. Mean age was 24.5 Ϯ 5.1 years; mean height 173.5 Ϯ 10.2 cm and a mean weight of 77.5 Ϯ 8.9 kg. The McMaster University Human Ethics Committee approved the study and participants were advised of the risks before providing written informed consent.
Preliminary testing
Participants' maximal aerobic power (V O 2 Peak ) was assessed by a standard continuous progressive loading protocol on an electrically braked cycle ergometer (Eric Jaeger, Hoechberg, Germany). Expired gases were measured using a computerised open circuit gas collection and analysis system. Expired gases were collected and oxygen consumption was calculated every 30 s during the test until fatigue. V O 2 Peak was determined as the highest oxygen consumption (averaged over 1 min) achieved during the test. Details of this testing have been previously described.
2
Protocol
Participants reported to the laboratory after a 4-h fast on two separate occasions separated by at least 14 days. For 11 days prior to each trial, in a randomised order, participants ingested either placebo (sucrose) or an SSRI (Paroxetine HCl, 20 mg per day). During the 4 days immediately preceding each trial, ingested food was kept constant by having the participants consume identical meals and portions. For the final 2 days participants consumed pre-packaged diets free from any stimulants or depressants known to affect blood pressure (eg, caffeine and alcohol) and void of any foods known to be high in tryptophan. Additionally, no formal exercise was performed during this period. Upon arriving at the laboratory, a 3.8 cm, 20-gauge catheter was inserted into the radial artery and coupled to a saline-Heparin (Wyeth-Ayerst, Toronto, ON, Canada) drip equipped with a pressure transducer (Novotrans, MX 800, Medex, Hilliard, OH, USA) for the direct measurement of blood pressure. This transducer was placed at mid-sternal level and coupled to an amplification system (Acudata, model 143, Honeywell, Denver, CO, USA) and an on-line data acquisition package (Windaq/200, DataQ Instruments, Akron, OH, USA) sampling at a frequency of 500 Hz. Calibration of the pressure monitoring system was completed using a mercury manometer before each trial. The system was calibrated to show a linear response between 0 and 300 mm Hg. Participants were also fitted with signal triggered ECG harness for recording of the QRS complex. Participants then remained in a seated, resting position for a minimum of 30 min before the collection of baseline measurements. After a 5-min recording of baseline blood pressure and HR, participants completed 30 min of cycle ergometry at a power output eliciting 70% of V O 2 Peak . Blood pressure, HR and V O 2 were monitored throughout, with 4-min windows saved to disk at 15 and 30 min of exercise for later analysis. For trial 2, power output was kept consistent with trial 1.
After cycling, the participants remained quietly seated for 90 min. During this period, blood pressure and HR were continuously monitored with 4-min windows saved to disk spanning 5, 10, 15, 30, 45, 60, 75 and 90 min post exercise (ie, for the 5-min reading, blood pressure was collected from min 3 to min 7). V O 2 was recorded subsequent to blood pressure recordings at 15, 30, 45, 60, 75 and 90 min post exercise. Additionally, arterial blood samples were drawn subsequent to blood pressure recordings at rest, 30 min of exercise and 5, 15, 30, 60 and 90 min post exercise for analysis of 5-HT, its major metabolite, 5-hydroxyindole acetic acid (5-HIAA), adrenaline and noradrenaline as outlined below. HR was recorded at three equidistant times during each segment and the average was taken as the HR for that segment. The two trials were performed at the same time each day and laboratory temperature and humidity was kept constant for each trial (22-24°C, 50% relative humidity).
5-HT And 5-HIAA assay
Blood collection: Blood was drawn into chilled plastic tubes containing acid citrate dextrose (ACD) (25 g sodium citrate dihydrate, 14 g citric acid and 20 g dextrose/l). Additionally, since platelets are known to be the major source of 5-HT in the periphery, the 1L stock ACD solution also contained a cocktail of platelet activation inhibitors (containing 400 l of 5 mg/ml prostaglandin E1, 400 l of 25 mg/ml leupeptin, and 1 ml of 250 mM phenylmethylsulfonyl fluoride) known to arrest platelet activation. Blood was centrifuged at 800 rpm for 20 min. The platelet-rich plasma was transferred to another chilled plastic tube and centrifuged at 2700 rpm for 9 min. Platelet-poor plasma was removed and stored at −50°C for future analysis.
Sample preparation: The plasma was thawed and duplicate 500-l samples were alioquated into chilled plastic vials. Fifty l of the internal standard, -methyl serotonin (50 ng) was added. Protein was precipitated with 100 l of ice cold 40% ( v / v ) percholoric acid and shaken for 10 min. Samples were spun at 4°C and 1000 g for 20 min and injected into the high pressure liquid chromatograph (HPLC).
Apparatus: The HPLC system consisted of an injector pump (Waters 510: Waters, MA, USA), an automated, refrigerated sample injector (Waters 712), a reverse phase analytical column (Microsorb C 8 , 4.6 ϫ 10 mm, Ranin, CA, USA), protected by a guard column (Waters C 8 , 2.9 ϫ 20 mm, Waters), and an electrochemical detector (ESA Coulochem II, SPD, ON, Canada.
HPLC conditions:
The mobile phase consisted of acetonitrile (10%), sodium monobasic phosphate (6.9 g/l), heptane sulfonic acid (250 mg/l), and ethylenediaminetetraacetic acid (EDTA) (80 mg/l). The solution was adjusted to pH 3.2 with o-phosphoric acid and filtered through 4 m membrane and degassed. The flow rate was set to 1.2 ml per min.
Adrenaline and noradrenaline assay
Blood collection: Blood was drawn into chilled glass tubes containing ethylene glycol aminoethyl ether tetraacetic acid and reduced glutathione (Cat a Kit: Amersham Chemical, ON, Canada) and centrifuged at 4°C and 3000 rpm for 10 min. The plasma Journal of Human Hypertension was transferred into chilled plastic tubes and stored at −50°C for future analysis.
Sample preparation: Plasma was thawed and duplicate 1 ml samples were alioquated into chilled plastic vials. Ten l of the internal standard, 3,4 dihydroxybenzylamine (DHBA) was added (9 ng), followed by 400 l of Tris buffer (243.6 g Tris/l, 2 g EDTA/L, pH 8.8) and 10 mg alumina oxide. Samples were vortexed for 30 s and then shaken for 10 min. After centrifugation for 2 min, the supernatant was discarded. The alumina oxide was washed three times with 9ϫ distilled water. Catecholamines were extracted from the alumina using 100 l of .25N acetic acid and injected into the HPLC.
Apparatus: The HPLC system was as above, with the substitution of the reverse phase analytical column (Symmetry Shield RP 8 , 3.9 ϫ 150 mm: Waters).
HPLC conditions:
The mobile phase consisted of methanol (3%), sodium monobasic phosphate (6.9 g/l) heptane sulfonic acid (250 mg/l), and EDTA (80 mg/l). The solution was adjusted to pH 3.6 with o-phosphoric acid and filtered through 4 m membrane and degassed. The flow rate was set to 1.5 ml per min.
Power spectral analysis of heart rate variability (HRV)
To assess the potential contribution of the autonomic nervous system in PEH, we used power spectral analysis of HRV. For a review on this procedure, see Kamath and Fallen. 17 Briefly, the time series of the HR data was linearly interpolated on an xy series to a standard interval series that can be numerically processed using standard fast fourier transformation (FFT) techniques. Data was then filtered using a lowpass Butterworth filter followed by a Hammond window. Power spectral density was calculated and then integrated and normalised. Data falling above 0.15 Hz was considered high frequency and data falling below 0.15 Hz was considered low frequency. The low frequency area to high frequency area ratio was calculated and considered indicative of sympathetic activity. The high frequency to total area was calculated as a measure of parasympathetic activity.
Haemodynamic analysis
Blood pressure waveforms were analysed using the Windaq data analysis program (DataQ Instruments, Akron, OH, USA). Systolic (SBP) and diastolic (DBP) blood pressure were calculated as the highest point and lowest point prior to the last inflection point in the waveform, respectively. The quotient of the integrated pressure and the duration of the time interval determined mean arterial pressure (MAP). Pulse pressure (PP) was taken as the difference
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between SBP and DBP. The rate pressure product (RPP) was calculated as the product of the HR and the SBP divided by 1000.
Statistical analysis
All data were analysed using repeated measures multiple analyses of variance (Statistica, Statsoft, OK, USA). Significant findings were assessed using the Tukey honestly significant difference (HSD) post hoc comparison. All values are expressed as means Ϯ s.d. unless otherwise noted.
Results
Arterial blood pressure responses
The SSRI intervention was found to have no effect on any of the arterial blood pressure responses. As shown in Figure 1 , there was a significant (P Ͻ 0.01) increase in both SBP (145 Ϯ 15 to 185 Ϯ 19 mm Hg) and DBP (72 Ϯ 10 to 79 Ϯ 10 mm Hg) during the exercise. Thereafter, DBP returned to pre-exercise values for the duration of the 90-min post exercise monitoring period. SBP was significantly decreased from baseline measurements during the initial 60 min following exercise. The nadir of the pressure decrement occurred 5 min after exercise (122 Ϯ 18 mm Hg) and gradually increased towards baseline over the following 55 min, after which SBP had returned to normal.
Compared with pre-exercise, there was a significant (P Ͻ 0.01) increase in MAP (92 Ϯ 12.0 to 107 Ϯ 11 mm Hg) during exercise (Figure 1 ). MAP decreased below baseline values during the initial 5 min following exercise (87 Ϯ 13 mm Hg) and returned to normal for the remainder of the post exercise monitoring period.
Across trials, PP was significantly (P Ͻ 0.01) increased during the exercise (73 Ϯ 9 to 106 Ϯ 17 mm Hg). Post exercise PP was reduced from preexercise values for 75 min, after which it had returned to normal. The nadir of the PP decrement occurred 5 min after exercise (53 Ϯ 11 mm Hg) and then gradually increased towards pre-exercise levels.
HR response
As expected, HR increased significantly above preexercise values during the exercise bout (P Ͻ 0.01) (66 Ϯ 9 to 171 Ϯ 16 beats/min). Post exercise, HR steadily declined until baseline values were reattained after 75 min.
Rate pressure product
As an indicator of myocardial oxygen demand and cardiac work, the rate pressure product (RPP) was significantly (P Ͻ 0.01) increased during exercise from a resting measure of 9.5 Ϯ 1.4 to 30.9 Ϯ 4.2. The RPP steadily declined until pre-exercise values were re-established by 30 min following exercise.
Oxygen consumption
There was a minimal but significant (P Ͻ 0.05) main effect for oxygen consumption. The SSRI trial resulted in an elevated V O 2 as compared to the placebo trial (0.808 Ϯ 0.97 vs 0.768 Ϯ 0.96 l/min). Additionally, across both trials, V O 2 was significantly (P Ͻ 0.01) elevated during exercise (0.245 Ϯ 0.06 to 2.575 Ϯ 0.35 l/min), but returned to preexercise levels by 15 min post exercise.
Catecholamines
As shown in Figure 2 , the SSRI had no effect on catecholamine concentrations. Adrenaline was significantly (P Ͻ 0.01) increased from baseline values during exercise (0.60 Ϯ 0.14 ng/ml to 1.3 Ϯ 1.6 ng/ml). Resting values were re-established by 5 min post exercise. Similarly, noradrenaline values were significantly (P Ͻ 0.01) elevated with exercise (0.27 Ϯ 0.31 ng/ml to 4.58 Ϯ 2.1 ng/ml). Noradrenaline had returned to pre-exercise levels within 15 min after exercise. 
Indolamines
Peripheral measures indicated significant effects of the SSRI on indolamine levels (Figure 3 ). Plasma levels of 5-HT were significantly (P Ͻ 0.01) reduced across the SSRI trial as compared to the placebo trial (2.2 Ϯ 3.1 vs 10.2 Ϯ 12.7 ng/ml).
Due to high variability, levels of plasma 5-HIAA failed to show significant (P Ͼ 0.05) differences, although values were augmented by ෂ13% during the SSRI intervention (539 Ϯ 269 vs 471 Ϯ 303 ng/ml).
Power spectral analysis of HRV
HRV showed that the low frequency to high frequency area (an indication of sympathetic activity) significantly increased at 10 and 15 min post exercise (P Ͻ 0.05), after which it had returned to preexercise measures. The high frequency to total area (indicative of parasympathetic activity) was significantly (P Ͻ 0.01) increased at 5 min and decreased at 15 min post exercise. All other time points did not differ from baseline values. Figure 3 The effects of SSRI treatment on peripheral measures of indolamine levels. *Indicates a significant difference from placebo (n = 11).
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Discussion
Our results indicate that in our borderline hypertensive participants, an 11 day treatment of paroxetine 20 mg/day, used to alter central serotonin levels, did not influence the magnitude or duration of PEH. Lemberger et al 18 found 63% inhibition of serotonin reuptake inhibition achieved after 1 week of a similar SSRI treatment. Given this, and the significant decrease in peripheral 5-HT levels while under SSRI treatment (which was expected due to the drug induced down regulation of peripheral production) and no change (and in fact a non-significant increase) in 5-HIAA, the major 5-HT metabolite, in our study we are confident that brain 5-HT was elevated during and following exercise in the SSRI trial. This contradicts the findings of a previous study in rats 3 that suggested that PEH is influenced by the serotonergic system. However, in that study exercise was simulated by stimulation of the sciatic nerve and thus differs from voluntary exercise. Other differences have been found between the rodent and human models investigating the existence, magnitude and potential mechanisms of PEH. For example, in the rodent model, Hoffmann et al 1 elegantly showed that binding of ␤-endorphin to the , and to a lesser extent the ␦-receptors, was responsible for PEH in rats. However, human studies that have examined the contribution of the ␤-endorphins to PEH by blocking the system with naloxone have elicited contradictory results. 7, 10 The concentrations of peripherally circulating 5-HT in the present study were considerably lower than those found in other studies (eg, Steinberg et al 19 ). We attribute this to our control to 5-HT release from platelets. Platelets are the primary storage vesicle for 5-HT in the periphery. It is known that clotting factors released at the arterial/venous puncture, as well as collection procedures, can cause platelet release of 5-HT. Without the addition of platelet release inhibitors, as in the present study, it is likely that substantial increases in 5-HT will occur, and therefore not be indicative of 5-HT release from the brain and peripheral production sites such as the gut and intestines.
We have recently demonstrated that PEH is not simply due to participants maintaining a resting position for long periods of time. 2 We are therefore confident that the transient but significant decrements in blood pressure documented here are a result of the exercise interventions. As in our previous studies 2,4-6 and elsewhere 20, 21 blood pressure tended to return towards baseline within the initial 60 to 90 min post exercise. Other studies have concluded that PEH may persist for up to 17 h (eg, J Hagberg, personal communication). Taken together, it is plausible that prolonged oscillations in blood pressure might persist for up to 12 h following exercise. 22 An interesting and unexpected finding from the present study was that V O 2 was elevated in the SSRI condition. Paired t-tests indicated that this effect was not present before exercise, indicating that an interaction had occurred between the drug intervention and exercise. Although this may lend support to the central fatigue hypothsis of exercise, we will not discuss such implications here as it is beyond the scope of the present study.
Heart rate did not return to resting values until 75 min post exercise. This lengthy interval may be related to the fact that the participants in the present study were untrained. Furthermore, it has been suggested that a borderline hypertensive population, as in the present study, may have an increased sympathetic outflow. 23 This increased outflow, coupled with the (non-significant) traces of circulating catecholamines post exercise could also contribute to the increased heart rate post exercise. However, our finding that hypotension still occurred, despite the increased heart rate and elevated noradrenaline indicates the robustness of the PEH phenomenon.
It is interesting to note that the relative contribution of the SNS, as indicated by HRV, was increased during a portion of the PEH. Others who have measured HRV during PEH have found conflicting results. 23, 24 However, similar to our results, Piepoli et al 25 also found an increased SNS activity and attributed this to a compensatory, reflex mechanism to the observed hypotension.
The varied results found between mechanisms of PEH such as muscle sympathetic nerve activity, the opioid system as well as the major differences in the existence, magnitude and response of PEH suggest that it is a phenomenon that is not caused by a single factor. A complex matrix of blood pressure regulating factors including both central and peripheral mechanisms are likely responsible for PEH and require further investigation.
